Gani, Rafiqul

Gernaey, Krist

Muller, frans

Rozada-Sanchez, Raquel

Singh, Ravendra

Woodley, John

Wrate, Tim

There is a significant cost associated with process development of a portfolio of pharmaceutical products, few of which will reach the market. Continuous processing will increase the “chemical space” which can increase development efficiency. For example one, particularly attractive option is to develop manufacturing processes based on modular continuous systems; a flexible generic continuous modular plant which can be adapted for different substrates. In the work reported here, a substrates adoption methodology (SAM) has been developed. The proposed SAM identifies the necessary changes to a template recipe &amp; flowsheet in order to adapt it for a given substrate. The changes can be related to reagents (e.g. reducing agent, solvent, catalyst), process conditions (e.g. operating temperature, flow rates), as well as in the physical arrangement (configuration) of the modular process equipment within the template. In this way the substrates adoption methodology helps to achieve “fast, flexible, future (F3)” pharmaceutical production processes by adapting a recently designed generic modular process-plant. The supporting tools for the substrate adoption are: (1) an ontological knowledge-base consisting of the properties of substances, reaction characteristics and characteristics of unit operations; and (2) a model library consisting of the mathematical models. The objective of this presentation is two-fold: First to highlight the substrates adoption framework and the associated models, methods and tools, and second to demonstrate its applications using a pharmaceutical manufacturing case study involving the nitro reduction of 2-Nitro-4’-chlorodiphenylamine

Online Research Database In Technology

                       General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.  • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal   If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.     Downloaded from orbit.dtu.dk on: Dec 18, 2017Substrates adoption methodology (SAM) to achieve “Fast, Flexible, Future (F3)”pharmaceutical production processesSingh, Ravendra; Rozada-Sanchez, Raquel; Wrate, Tim; Muller, frans; Gernaey, Krist V.; Gani, Rafiqul;Woodley, JohnPublication date:2011Document VersionPublisher's PDF, also known as Version of recordLink back to DTU OrbitCitation (APA):Singh, R., Rozada-Sanchez, R., Wrate, T., Muller, F., Gernaey, K., Gani, R., & Woodley, J. (2011). Substratesadoption methodology (SAM) to achieve “Fast, Flexible, Future (F3)” pharmaceutical production processes.Abstract from 8th European Congress of Chemical Engineering, Berlin, Germany.Substrates adoption methodology (SAM) to achieve “Fast, Flexible, Future (F3)1” pharmaceutical production processes Ravendra Singh1, Raquel Rozada-Sanchez2, Tim Wrate2, Frans Muller2, Krist V. Gernaey1, Rafiqul Gani1, John M. Woodley1 1Department of Chemical and Biochemical Engineering, Technical University of Denmark, DK-2800 Lyngby, Denmark 2AstraZeneca Limited, Charter Way, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, UK There is a significant cost associated with process development of a portfolio of pharmaceutical products, few of which will reach the market. Continuous processing will increase the “chemical space” which can increase development efficiency. For example one, particularly attractive option is to develop manufacturing processes based on modular continuous systems; a flexible generic continuous modular plant which can be adapted for different substrates. In the work reported here, a substrates adoption methodology (SAM) has been developed. The proposed SAM identifies the necessary changes to a template recipe & flowsheet in order to adapt it for a given substrate. The changes can be related to reagents (e.g. reducing agent, solvent, catalyst), process conditions (e.g. operating temperature, flow rates), as well as in the physical arrangement (configuration) of the modular process equipment within the template. In this way the substrates adoption methodology helps to achieve “fast, flexible, future (F3)” pharmaceutical production processes by adapting a recently designed generic modular process-plant. The supporting tools for the substrate adoption are: (1) an ontological knowledge-base consisting of the properties of substances, reaction characteristics and characteristics of unit operations; and (2) a model library consisting of the mathematical models. The objective of this presentation is two-fold: First to highlight the substrates adoption framework and the associated models, methods and tools, and second to demonstrate its applications using a pharmaceutical manufacturing case study involving the nitro reduction of 2-Nitro-4’-chlorodiphenylamine.                                             1 F3 Factory project, European Community‘s 7th Framework Program under grant agreement n° 228867 http://www.f3factory.com/scripts/pages/en/home.php 

Substrates adoption methodology (SAM) to achieve “Fast, Flexible, Future (F3)” pharmaceutical production processes

http://orbit.dtu.dk/ws/files/5814146/RS_ECCE8_Abstract.pdf

Substrates adoption methodology (SAM) to achieve “Fast, Flexible, Future (F3)” pharmaceutical production processes

Abstract

Similar works

Full text

Available Versions

Online Research Database In Technology